VC-backed Biosergen raises €5m via unit offering ahead of IPO

The company, which is backed by Östersjöstielsen (The Baltic Sea Foundation), Rosetta Capital, Sintef Venture and Karolinska Development, will use the the proceeds from the offering to launch clinical trials of its antifungal drug candidate BSG005 with the plan of filing for market approval in the US and Europe by the end of 2025.

The company expects to start trading on Nasdaq First Growth Market on 24 June.

Östersjöstielsen, Rosetta and Sintef together hold a 91.2% stake in Biosergen, while Karolinska Development owns 3.2%. 

Company
Founded in 2004 and based in Solna, Biosergen is a biotech company developing new antifungal drugs for the treatment of severe invasive fungal infections. 

Advisers
Company – Lindahl (legal). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Nordics
• Healthcare
• Sweden
• IPO
• Nordic healthcare